Given the well-established association between the APOEε4 allele and an increased risk for AD, it is understandable that some laboratories and healthcare providers express caution regarding the ordering or offering of APOE testing (i.e., in dyslipidemia genetic panels) (Ison et al., 2024). The gene discussed is APOE; the disease is Alzheimer disease.